Isupetasys (007660) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Isupetasys KRW 26,896, price KRW 118,900, upside -77.4%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Isupetasys for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3,276 KRW – 161,400 KRW · fair‑value band 14,130 KRW – 45,964 KRW · the 118,900 KRW price screens above the 26,896 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Isupetasys in your weekly email
Every Wednesday you see whether Isupetasys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ISU Petasys Co., Ltd. manufactures and sells printed circuit boards (PCBs). The company offers network equipment, including router/switch and backplane; server/storage PCB; supercomputer high-performance computing PCB; aerospace PCB; and IC testers, including probe card, load board, and burn-in board.
Show more
ISU Petasys Co., Ltd. manufactures and sells printed circuit boards (PCBs). The company offers network equipment, including router/switch and backplane; server/storage PCB; supercomputer high-performance computing PCB; aerospace PCB; and IC testers, including probe card, load board, and burn-in board. It also provides advanced driver assistance system RF radar PCBs; and radio frequency (RF) PCBs. The company was formerly known as Petasys Co., Ltd. and changed its name to ISU Petasys Co., Ltd. in March 2002. ISU Petasys Co., Ltd. was founded in 1972 and is headquartered in Daegu, South Korea.
Stock analysis
Isupetasys (007660) currently trades at 118,900 KRW, while our model-based Fair Value estimate is 26,896 KRW, implying the stock looks roughly 342.1% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 41,882 KRW per share, and 0 of the 26 models we run sit above the 118,900 KRW price.
Bear case: the Asset-Based group reads lowest at 6,895 KRW, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 14,130 KRW (bear) to 45,964 KRW (bull), the price of 118,900 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Isupetasys reported revenue of 1.1T KRW in FY2025 versus 470B KRW in FY2021, a compound +23.4%/yr. Reported net income was 160B KRW in FY2025.
Key figures
Market cap 8.7T KRW (≈ $6.1B) · P/S ratio 7.55 · Dividend yield 0.2% · Net margin 14.7% · Return on equity 29.9% · Return on assets (EBIT) 14.1% · Operating margin 19.8% · Revenue (TTM) 1.2T KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 101% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Technology peers we cover trades at −65% fair-value upside, at −77%, 007660 screens richer than that median.
Fair Value models
Bear 14,130 KRWFair Value 26,896 KRWBull 45,964 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+30.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.2%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.2%
Dividend (yield on the price)0.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 19%
2025 sits 92% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+35.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +32.8% a year for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Electronic Components · 644 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−77% · Bottom 25%
Profitability
Return on equity (TTM)30% · Top 25%
Return on assets13% · Top 25%
Net margin (TTM)15% · Top 25%
Operating margin (TTM)20% · Top 25%
Growth and dividend
Revenue growth35% · Top 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Electronic Components median · lower = cheaper
P/FCF0.4× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 40
PAST (return on equity)100· sector 25
HEALTH (low debt)93· sector 95
DIVIDEND (yield)4· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Isupetasys Fair Value". https://www.fairvalue-calculator.com/stock/007660
Frequently asked questions
Is Isupetasys (007660) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 26,896 KRW versus a price of 118,900 KRW, about −77% upside (overvalued).
What is the fair value of 007660?
Our model-based fair value for Isupetasys is 26,896 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 118,900 KRW.
What is the quality score of 007660?
Isupetasys has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Isupetasys (007660)?
Our model-based price target is the fair value of 26,896 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 14,130 KRW, optimistic scenario 45,964 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Isupetasys stock forecast for 2026?
Our models put fair value at 26,896 KRW, about −77% upside versus a price of 118,900 KRW (overvalued). Cautious scenario 14,130 KRW, optimistic scenario 45,964 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Isupetasys (007660)?
Isupetasys reported trailing-twelve-month revenue of about 1.2T KRW (latest available figure, as of Sep 24, 2026).
Does Isupetasys pay a dividend?
Isupetasys currently shows a dividend yield of about 0.19% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Isupetasys (007660)?
For today's price to be fair in a discounted-cash-flow model, Isupetasys would have to grow free cash flow by more than 80 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 007660 use?
Our models discount Isupetasys at 11.2 %: a base by market capitalisation (mega), damped by beta 1.91, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Isupetasys that is more than 80 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Isupetasys (007660) delivered so far?
Over the past 5 years revenue at Isupetasys grew +16.2 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Isupetasys (007660) growing?
The median revenue growth in the sector is +8.4 % a year. That is the yardstick for the growth priced into Isupetasys (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Isupetasys (007660)?
The free-cash-flow yield on the price is 0.16 %: that much free cash flow Isupetasys produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Isupetasys (007660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Isupetasys it is 26,896 KRW per share (as of Sep 24, 2026), against a price of 118,900 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Isupetasys stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 007660 trades above its calculated fair value: price 118,900 KRW, fair value 26,896 KRW, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 007660?
No. The price is what the market pays today (118,900 KRW); the fair value is what the company's own numbers justify (26,896 KRW). For Isupetasys the two are 92,004 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Isupetasys worth?
The market values Isupetasys at about 8.7T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 118,900 KRW; our models calculate a fair value of 26,896 KRW per share.
What do the bullish and bearish scenarios say about 007660?
Our models span a range for Isupetasys: cautious scenario 14,130 KRW, base 26,896 KRW, optimistic 45,964 KRW per share (as of Sep 24, 2026, price 118,900 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Isupetasys (007660)?
Balance-sheet figures for Isupetasys (as of Sep 24, 2026): return on equity 29.9%, debt of 0.13 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 007660 from its 52-week high?
Isupetasys trades at 118,900 KRW, about 26% below its 52-week high of 161,400 KRW and 101% above the low of 59,200 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 26,896 KRW is for.
Which stocks are comparable to Isupetasys?
From the same area (Technology) we also value Amphenol Corporation, Delta Electronics, Inc, Corning Incorporated, Luxshare Precision Industry Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Isupetasys stock attractive at the current price?
The data as of Sep 24, 2026: price 118,900 KRW, calculated fair value 26,896 KRW (−77%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 007660 calculated?
We run Isupetasys through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 26,896 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Isupetasys itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Isupetasys (007660)?
The closing price on Sep 23, 2026 was 118,900 KRW. Our model-based fair value is 26,896 KRW, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Isupetasys right now?
The price sits above even our optimistic bull case (45,964 KRW). The favourable scenario is already priced in. The model range is unusually wide (14,130 KRW to 45,964 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Isupetasys
How large is the market capitalisation of Isupetasys (007660)?
The market capitalisation of Isupetasys is 8.7T KRW (≈ $6.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Isupetasys (007660)?
The price-to-sales ratio of Isupetasys is 7.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Isupetasys (007660)?
The dividend yield of Isupetasys is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Isupetasys (007660)?
The net margin of Isupetasys is 14.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Isupetasys (007660)?
The return on equity (ROE) of Isupetasys is 29.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Isupetasys (007660)?
On an EBIT basis the return on assets of Isupetasys is 14.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Isupetasys (007660)?
The operating margin of Isupetasys is 19.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Isupetasys (007660)?
Revenue at Isupetasys is growing +34.8% versus a year earlier (3y avg +19.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Isupetasys (007660)?
Earnings per share at Isupetasys are growing +13.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Isupetasys (007660) carry?
The net debt of Isupetasys is 72.2B KRW (fiscal year 2025, ≈ 5.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Isupetasys in the live analysis
One click puts Isupetasys on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
